Dosimetry in Molecular Radiotherapy for Personalized Patient Treatments

Closed for proposals

Project Type

Coordinated Research Project

Project Code




Approved Date

13 February 2017


3 - Active - Ongoing

Start Date

10 July 2017

Expected End Date

31 December 2021

Participating Countries

South Africa
United States of America


Radiopharmaceutical therapy (RPT) can be broadly defined as the use of radionuclides to deliver radiation lethal to tumour cells. Radiation delivery in RPT involves the use of pharmaceuticals that either bind specifically to tumours or accumulate by a broad array of physiologic mechanisms. The efficacy of RPT depends upon delivering a lethal level of radiation to tumour cells while sparing normal cells. The ability to image the biodistribution of RPT agents and use this information to evaluate the absorbed dose has been seen as an unnecessary logistical and financial expense of the treatment. However, in the context of drug development and optimization, the ability to image and calculate normal organ and tumour absorbed doses, provides a number of advantages because these variables are more closely related to biological response. A dosimetry-driven treatment-planning approach to RPT translates into accounting for patient-specific pharmacokinetic and tumour and normal organ radioactivity localization differences by imaging. Such differences in absorbed dose estimates are considered which, in contrast to the amount of radioactivity administered (activity), account for individual patient pharmacokinetics, the properties of the radionuclide, and organ anatomy. Internal dosimetry is generally not integrated in the clinical practice mainly due to a lack of standardized methods, training and resources. Under the framework of the CRP participants are expected to (i) contribute to the coordinated research activities, designed to test and standardize dosimetric methods and assess the typical accuracy with which dosimetry can be reached in nuclear medicine practice and (ii) propose individual research activities in the field of dosimetry for RPT that are of local interest. Through this CRP, participants will develop abilities to be engaged into state of the art research in the field of dosimetry in RPT, with a direct impact to both the clinical services and the research potential of the Member States.


The overall objective of this project is to enhance the capabilities of Member States to incorporate dosimetry in RPT practice. The ultimate benefit will be to patients receiving individualized RPT so as to make this treatment modality safer and more effective.

Specific objectives

Assess and investigate ways to improve the achievable accuracy of tumour and normal tissues absorbed doses

Identify the advantages of implementing dosimetry in terms of reducing toxicity and improving tumour response

Establish an understanding of tools and methods available for dosimetry of RPT

Create scientific networks with expertise in dosimetry for RPT that will remain active after the completion of the CRP

Support participating institutes to become reference centres on RPT for their Member States

Contact the project officer


Stay in touch